Mawdsleys announces new solus deal with M&A Pharmachem
Mawdsleys announces new solus deal with M&A Pharmachem 9th June 2014

Mawdsleys is delighted to announce a new solus hospital distribution agreement with M&A Pharmachem.

 

From 1st July 2014, Mawdsleys  will become the sole distributor for all M&A Pharmachem contracted products into the hospital sector, which previously hospitals purchased from M&A directly.   As from this date, all orders for M&A products will need to be purchased via Mawdsleys.

 

The full range of M&A products will available through Mawdsleys, and customers will be able to;

 

Benefit from EDI or online ordering

 View invoices online

View contract prices online

View M&A stock availability online

Benefit from no minimum order levels

Purchase M&A products over labelled where required

Benefit from daily deliveries from your local depot

 

Stock will be available from 1st July 2014, and you can order your M&A Pharmachem products from Mawdsleys through your normal preferred route; i.e. fax, EDI, through the Mawdsleys online ordering system – E-Awards, or by calling your local depot.

 

Should you have any queries, please feel free to contact your local Mawdsleys Account Manager.

 

You may also contact Mawdsleys customer service on 0844 736 9016 or info@mawdsleys.co.uk

 

Your M&A contact is Beverley Byrne on 01942 816184

Other latest news
https://www.mawdsleys.co.uk/news/mawdsleys-donate-presents-to-children-of-manchester/ thumbnail image Mawdsleys donate presents to children of Manchester

Mawdsleys have proudly donated over 150 presents to the Key 103 Mission Christmas appeal for children living in poverty in Manchester.   The presents were collected in our Salford depot and delivered by a Mawdsleys' driver to Mission HQ in Trafford Park last week. The presents were donated by Mawdsleys'…

Read more
https://www.mawdsleys.co.uk/news/mawdsleys-and-meabco-launch-a-named-patient-supply-program-for-bp-c1/ thumbnail image Mawdsleys and Meabco launch a Named Patient Supply program for BP-C1

Mawdsleys and Meabco A/S have launched a Named Patient Supply program to allow Oncologists within the European Union (EU) to obtain access to BP-C1 on an unlicensed basis for the treatment of metastatic breast cancer and incurable pancreatic cancer.   BP-C1 is a new benzene-poly-carboxylic acids complex with cis-diammineplatinum (II)…

Read more